-
公开(公告)号:US4935493A
公开(公告)日:1990-06-19
申请号:US105768
申请日:1987-10-06
CPC分类号: C07K5/0827 , C07K5/0606 , C07K5/06191
摘要: A compound having the structure ##STR1## where T is of the fomrula ##STR2## where each D.sup.1 and D.sup.2, independently, is a hydroxyl group of a group which is capable of being hydrolysed to a hydroxyl group in aqueous solution at physiological pH; a group of the formula ##STR3## where G is either H,F or an alkyl group containing 1 to about 20 carbon atoms and optional heteroatoms which can be N, S, or O; or a phosphonate group of the formula ##STR4## where J is O-alkyl, N-alkyl, or alkyl, each comprising about 1-20 carbon atoms and, optionally, heteroatoms which can be N, S, or O; T being able to form a complex with the catalytic site of an enzyme, X is a group having at least one amino acid, ##STR5## and each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 is separately a group which does not interfere significantly (i.e., does not lower than Ki of the compound to less than 10.sup.-7 M) with site-specific recognition of the compound by the enzyme, and allows a complex to be formed with the enzyme.
摘要翻译: 具有结构
的化合物,其中T是所述的“IMAGE”,其中每个D1和D2独立地是能够在生理pH下在水溶液中水解成羟基的基团的羟基; 其中G是H,F或含有1至约20个碳原子的烷基和可以是N,S或O的任选的杂原子的式 或其中J为O-烷基,N-烷基或烷基的式(IMAGE)的膦酸酯基团,各自包含约1-20个碳原子,以及任选的可以是N,S或O的杂原子; T能够与酶的催化位点形成复合物,X是具有至少一个氨基酸的基团,每个R 1,R 2,R 3,R 4,R 5,R 6,R 7和R 8 分别是通过酶对化合物的位点特异性识别而不会显着干扰(即不低于化合物的Ki至小于10-7M)的基团,并且允许与酶形成复合物。 -
2.
公开(公告)号:US20110172149A1
公开(公告)日:2011-07-14
申请号:US12942313
申请日:2010-11-09
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译: 本发明提供了用于改变和调节葡萄糖和脂质代谢的方法和组合物,通常降低胰岛素抵抗,高血糖症,高胰岛素血症,肥胖症,高脂血症,高脂蛋白血症(如乳糜微粒,VLDL和LDL),并调节体脂肪和 更一般地,脂质储备,更一般地,用于改善代谢障碍,特别是与糖尿病,肥胖和/或动脉粥样硬化相关的那些。
-
3.
公开(公告)号:US07829530B2
公开(公告)日:2010-11-09
申请号:US12323751
申请日:2008-11-26
IPC分类号: A61K38/04
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.
摘要翻译: 本发明的一个方面涉及一种用于治疗动物的II型糖尿病的方法,包括以足以治疗动物的II型糖尿病的量联合给予二甲双胍和二肽基肽酶IV或其药学上可接受的盐的抑制剂 但不足以抑制动物的免疫系统。
-
4.
公开(公告)号:US08513190B2
公开(公告)日:2013-08-20
申请号:US13297522
申请日:2011-11-16
IPC分类号: A61K38/02
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.
摘要翻译: 本发明提供了通过向动物施用治疗有效量的二肽基肽酶IV(DPIV)或其药学上可接受的盐的抑制剂或其药学上可接受的盐来改变和调节II型糖尿病的方法,其中抑制剂具有抑制DPIV的Ki为10 nM或更少; 并且以足以治疗II型糖尿病但不足以抑制动物免疫系统的量施用抑制剂。
-
5.
公开(公告)号:US20120165252A1
公开(公告)日:2012-06-28
申请号:US13297522
申请日:2011-11-16
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译: 本发明提供用于改变和调节葡萄糖和脂质代谢的方法和组合物,通常降低胰岛素抵抗,高血糖症,高胰岛素血症,肥胖症,高脂血症,高脂蛋白血症(如乳糜微粒,VLDL和LDL),并调节身体脂肪和更一般 脂类储存,更一般地,用于改善代谢障碍,特别是与糖尿病,肥胖症和/或动脉粥样硬化相关的疾病。
-
6.
公开(公告)号:US20090082309A1
公开(公告)日:2009-03-26
申请号:US12323751
申请日:2008-11-26
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译: 本发明提供了用于改变和调节葡萄糖和脂质代谢的方法和组合物,通常降低胰岛素抵抗,高血糖症,高胰岛素血症,肥胖症,高脂血症,高脂蛋白血症(如乳糜微粒,VLDL和LDL),并调节体脂肪和 更一般地,脂质储备,更一般地,用于改善代谢障碍,特别是与糖尿病,肥胖和/或动脉粥样硬化相关的那些。
-
7.
公开(公告)号:US07459428B2
公开(公告)日:2008-12-02
申请号:US11487947
申请日:2006-07-17
IPC分类号: A61K38/04
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
摘要翻译: 本发明的一个方面涉及一种用于治疗动物的II型糖尿病的方法,包括以足以治疗动物的II型糖尿病的量联合给予二甲双胍和二肽基肽酶IV或其药学上可接受的盐的抑制剂 。
-
8.
公开(公告)号:US06890898B2
公开(公告)日:2005-05-10
申请号:US10190267
申请日:2002-07-03
IPC分类号: A61K45/00 , A61K31/00 , A61K31/137 , A61K31/15 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/46 , A61K31/48 , A61K31/69 , A61K31/702 , A61K38/00 , A61K38/05 , A61K38/28 , A61K38/55 , A61K45/06 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , A61P43/00 , C07K5/06 , A61K38/04
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译: 本发明提供了用于改变和调节葡萄糖和脂质代谢的方法和组合物,通常降低胰岛素抵抗,高血糖症,高胰岛素血症,肥胖症,高脂血症,高脂蛋白血症(如乳糜微粒,VLDL和LDL),并调节体脂肪和 更一般地,脂质储备,更一般地,用于改善代谢障碍,特别是与糖尿病,肥胖和/或动脉粥样硬化相关的那些。
-
9.
公开(公告)号:US08318669B2
公开(公告)日:2012-11-27
申请号:US12942313
申请日:2010-11-09
IPC分类号: A61K38/02
CPC分类号: A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.
摘要翻译: 本发明提供了通过施用治疗有效量的二肽基肽酶IV(DPIV)抑制剂或其药学上可接受的盐来修饰和调节胰高血糖素样肽1(GLP-1)代谢的方法,其中抑制剂具有抑制Ki DPIV为10nM以下; 并且以足以抑制GLP-1的DPIV蛋白水解的量的量施用抑制剂,但不足以抑制动物的免疫系统。
-
公开(公告)号:US07230074B2
公开(公告)日:2007-06-12
申请号:US10775598
申请日:2004-02-10
IPC分类号: C07K5/10
CPC分类号: C07F5/025
摘要: Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96–99 percent. The peptide inhibitors include one or more amino acids covalently coupled to boroproline moiety. The compounds are useful as DP-IV inhibitors, in vivo and in vitro.
摘要翻译: 提供IV型二肽基氨基肽酶(DP-IV)的肽抑制剂。 肽抑制剂的异构纯度约为96-99%。 肽抑制剂包括共价偶联到硼脯氨酸部分的一个或多个氨基酸。 该化合物在体内和体外可用作DP-IV抑制剂。
-
-
-
-
-
-
-
-
-